

MULTI-COUNTRY WESTERN PACIFIC INTEGRATED HIV/TB PROGRAMME

with the financial support of the Global Fund



*Empowered lives.
Resilient nations.*

RESULTS REPORT 2015-2017

MAY 2018



The views expressed in this publication are those of the authors and do not necessarily represent those of the United Nations, including UNDP, or UN Member States.

UNDP partners with people at all levels of society to help build nations that can withstand crisis, and drive and sustain the kind of growth that improves the quality of life for everyone. On the ground in more than 170 countries and territories, we offer global perspective and local insight to help empower lives and build resilient nations.

This document was supported by UNDP under the Multi-Country Western Pacific Programme.

Copyright © UNDP 2018

United Nations Development Programme
Pacific Office in Fiji
Level 2, Kadavu House
414 Victoria Parade
Suva, Fiji
Tel: +679 331 2018
Fax: +679 330 1718
Email: registry.fj@undp.org
Website: <http://www.pacific.undp.org/>

Design: Ian Mungall

Cover photo: Samoa Ministry of Health

SUMMARY

HIV and tuberculosis (TB) are the two most deadly infectious diseases in the world. Globally in 2016, TB took the lives of more than 1.7 million people,¹ while 1 million died from HIV-related illnesses.² TB is also the leading cause of death for people living with HIV, with about one-third of HIV-related deaths occurring as a result of the co-infection.

In the Western Pacific region, national HIV epidemics are low prevalence and generalized. However, HIV testing is low and there remains inadequate access to prevention, treatment, care and support services. Available data on sexually transmitted infections (STIs) from countries in the region reveal very high rates of chlamydia and relatively high rates of syphilis and gonorrhoea, especially when compared to other regions in the world. Behavioural data from a 2016 UNDP study showed that key populations were engaging in high risk behaviour, such as multiple sexual partners and unprotected sex.³ Furthermore, there are unsupportive policy and legal environments in many countries, such as criminalization of behaviours of key populations. High levels of stigma and discrimination have been reported by members of key population communities as well as people living with HIV.⁴

While there has been remarkable progress in the fight against TB in the Western Pacific region over the past two decades, the disease remains a major public health problem. The Pacific Island countries can be grouped broadly as high, moderate and low TB incidence areas. The high incidence countries (per 100,000 people) are Kiribati (566), Republic of the Marshall Islands (422), Federated States of Micronesia (177), Palau (123) and Nauru (112), while the low incidence countries are Vanuatu (56), Niue (20), Cook Islands (13), Tonga (8.6) and Samoa (7.7).⁵ The rate of Multi Drug Resistant (MDR) cases has been low on an average, with irregular cases detected in the high burden countries.

The Multi-Country Western Pacific Integrated HIV/TB Programme, with the financial support of the Global Fund (grant number: QMJ-C-UNDP), aims to improve the coverage and quality of HIV/TB prevention, treatment and care in 11 countries: Cook

1 WHO (2018). Tuberculosis Fact sheet. Accessible at <http://www.who.int/mediacentre/factsheets/fs104/en/>.

2 UNAIDS (2018). Fact sheet - Latest statistics on the status of the AIDS epidemic. Accessible at <http://www.unaids.org/en/resources/fact-sheet>.

3 UNDP, UNICEF, UNSW, ASHM, PSGDN (2016) Pacific Multi-Country Mapping and Behavioural Study: HIV and STI Risk Vulnerability among Key Populations.

4 FJN+ (2018) Overview Report of the People Living with HIV Stigma Index: Study in Seven Countries in the Pacific.

5 WHO (2017). Global tuberculosis report 2017.

Programme details	
Programme title:	Multi-Country Western Pacific Integrated HIV/TB Programme
Global Fund grant number:	QMJ-C-UNDP
Duration:	July 2015 – December 2017
Principal recipient:	UNDP Pacific Office in Fiji
Sub-recipients	Cook Islands Ministry of Health; Cook Islands Family Welfare Association; Federated States of Micronesia, Department of Health and Social Affairs; Fiji Network of People Living with HIV; Chuuk Women's Council; Kiribati Ministry of Health and Medical Services; Nauru Ministry of Health and Medical Services; Niue Department of Health; Pacific Sexual and Gender Diversity Network; Palau Ministry of Health; Republic of the Marshall Islands, Ministry of Health; Samoa Ministry of Health; Samoa Fa'afafine Association; Samoa Family Health Association; Tonga Family Health Association; Tonga Leitis Association; Tonga Ministry of Health; Tuvalu Family Health Association; Tuvalu Ministry of Health; Vanuatu Ministry of Health; Vatu Mauri Consortium (Vanuatu); Save the Children (Vanuatu)
Geographic coverage:	Cook Islands, Federated States of Micronesia, Kiribati, Marshall Islands, Nauru, Niue, Palau, Samoa, Tonga, Tuvalu and Vanuatu
Budget:	\$14.214 million

Islands, Federated States of Micronesia, Kiribati, Marshall Islands, Nauru, Niue, Palau, Samoa, Tonga, Tuvalu and Vanuatu. The grant has been implemented from 2015-2017 and received funding through a \$14.2 million grant from the Global Fund, with the United Nations Development Programme (UNDP) serving as Principal Recipient (PR).

The objectives of the programme are:

- Increase coverage of HIV prevention services, with a special focus on key populations and other vulnerable populations.
- Strengthen coverage and quality of treatment, care and support for people living with HIV, with special attention for adherence.
- Improve and expand use of strategic information to inform policy, programming, research and address structural barriers.

- Provide early rapid and quality diagnosis of TB, MDR-TB, TB/diabetes mellitus (DM) and TB/HIV with specific focus on screening and diagnosis in selected and prioritized hard to reach vulnerable groups.
- Sustain high quality treatment for all forms of TB including drug-resistant TB and HIV-related TB with patient support.
- Prevent TB through diagnosis and treatment of latent TB infection for high risk groups and scaling up of infection control measures.

The programme's objectives align with UNDP's new Strategic plan and contribute to countries' achievement of the Sustainable Development Goals (SDGs) and the commitment to leave no one behind. Specifically, the grant contributes to achieving SDG 3 (health and well-being) and its target to end the epidemics of AIDS and TB by 2030; the health-related targets of SDG 1 (reducing poverty); SDG 5 (gender equality); SDG 16 (peace, justice and strong institutions); and SDG 17 (partnerships for the goals).

At the national level, the grant is implemented in collaboration with 22 Sub-Recipients (SRs). In addition, the World Health Organization (WHO), Pacific Community (SPC) and Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine / Oceania Society for Sexual Health and HIV Medicine (ASHM-OSSHM) provide technical assistance to the programme.

Key achievements of the programme

Over the period 2015-2017, the programme has made significant progress towards responding to HIV and TB in the Pacific, including:

- Strengthened capacity of SRs to improve health governance, programme implementation and grant management, including technical support to develop activities addressing potential drivers of HIV risk vulnerability such as gender-based violence and legal barriers disproportionately affecting key populations.
- Reviewed and updated national guidelines in line with the latest WHO guidelines for antiretroviral drugs (ARVs), prevention of parent to child transmission (PPTC), STI diagnostics, HIV diagnostics and TB guidelines for Nauru, Cook Islands, Federated States of Micronesia, Kiribati and Niue.
- Following a comprehensive needs assessment, a mentorship mechanism and programme was developed linking HIV and TB medicine experts from around the region (including from Papua New Guinea, Fiji, Australia and New Zealand).

- Raised awareness on HIV, STIs and TB through an innovative mass media campaign as part of a public-private partnership with Digicel and Ministries of Health and other national partners in Samoa, Tonga and Vanuatu.
- Improved integrated programme performance: 63 percent of TB patients tested for HIV; 83 percent of pregnant women know their HIV status; 100 percent of people living with HIV on antiretroviral treatment (ART); 87 percent of pregnant women tested for syphilis; and 100 percent of people living with HIV on ART for 12 months after initiation (60 percent on ART overall).
- Procurement with cost savings for all programme countries of ARVs, HIV diagnostics commodities and equipment, laboratory supplies and support to forecasting and quality assurance for HIV and TB services delivery.
- Enhanced diagnostics capacity for HIV, STIs and co-morbidities through the supply and use of GeneXpert technology.
- Enhanced diagnostics capacity for TB mass screenings through the supply of mobile x-ray machines, with training and roll-out to take place in 2018.
- Technical capacity development for procurement and supply chain management (using m-supply software).
- Evidence from a multi-country behavioural study on key populations conducted in 2016 has been used to inform and develop country level programmes.
- Specific community outreach and facility-based HIV prevention activities delivered for men who have sex with men, transgender people, sex workers (female, male and transgender) and women attending antenatal care.
- Capacity development of civil society organizations (CSOs) that are representative of marginalized communities, including LGBTI organizations and women's councils. This has led to more CSO SRs and balancing the ratio of government SRs to CSO SRs.
- Technical support for creating an enabling legal environment, including dedicated support, advocacy and facilitation of a policy dialogue in the Cook Islands.
- Developed strategic information through a multi-county Stigma Index study covering seven countries in the region. The data generated will help to inform programmes, interventions and policies to ensure more effective HIV responses.

Programme performance highlights, 2015-2017



39

people currently on HIV treatment (2017)

532

men who have sex with men, transgender people and sex workers reached with HIV prevention packages

344

men who have sex with men, transgender people and sex workers reached with HIV counselling and testing

100%

of all HIV positive pregnant women received treatment to reduce mother to child transmission



52% → 58% → 62%

Increasing percentage of TB patients tested for HIV since 2015

1,066

cases of TB detected and put on treatment

TB treatment success rate has been above **80%** since 2015

KEY RESULTS BY COUNTRY AND SUB-RECIPIENT

Cook Islands

Cook Islands Ministry of Health (MOH), Cook Islands Family Welfare Association (CIFWA)

Major achievements:

- MOH and CIFWA collaborated with the Te Tiare Association (TTA) to improve services for key populations, especially transgender people. Funding was also provided to support TTA operations, including for office space, office furniture, computers and printers, and for a Programme Coordinator.
- Increased engagement between MOH, civil society and community organizations in annual World AIDS Day commemorations.
- Since 2016, have up scaled HIV and STI counselling and testing, as well as increased the number of tests conducted and results reported.
- Improved access to and distribution of awareness and health promotion materials, including condoms and lubricants.
- Workshops conducted on sexual and reproductive rights of women and girls.
- Reviewed and updated national guidelines on HIV, STIs and TB to align with the latest WHO guidelines.
- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- Health workers, including laboratory and antenatal clinic staff, trained on the SD Duo rapid diagnostic test for HIV and syphilis. The pilot phase has been completed and the tool is now being rolled out country-wide.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- As part of efforts to improve the quality of TB laboratory services, an on-site supervisory evaluation of the National TB Laboratory was conducted by the Pacific Paramedical Training Centre. A report with recommendations for lab improvements was developed and submitted.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOH	\$61,914.00	\$32,873.00	\$70,390.68	\$75,579.30	\$106,865.14	\$108,452.30
CIFWA			\$67,971.21	\$70,590.85	\$67,971.21	\$70,590.85
Total	\$61,914.00	\$32,873.00	\$138,361.89	\$146,170.15	\$174,836.35	\$179,043.15

Procurement

Classification	2016	2017	Total
Capacity Development & Building	\$5,513.00	\$14,251.31	\$19,764.31
Condoms & Lubricants	\$1,059.58	\$868.20	\$1,927.78
HIV/STI/TB Lab Reagents	\$1,922.93	\$4,631.07	\$6,554.00
IEC Materials & Media Campaign	\$150.00	\$20.00	\$170.00
IT Equipments & Printer		\$790.00	\$790.00
Medical Equipments		\$17,500.00	\$17,500.00
Other Items		\$594.70	\$594.70
Pharmaceuticals	\$62.95	\$121.20	\$184.15
Total	\$8,708.46	\$38,776.48	\$47,484.94

Performance against key programme indicators, Cook Islands

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	NA	N/A	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	NA	13	0
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	NA	13	0
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	NA	N/A	100%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	NA	N/A	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	NA	96%	95%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	NA	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	NA	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	NA	96%	96%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	NA	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	NA	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	NA	N/A	N/A
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	NA	2	0
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	NA	2	0
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	NA	N/A	100%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	NA	N/A	100%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	NA	100%	N/A
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	NA	N/A	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	NA	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	NA	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	NA	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

Federated States of Micronesia

Department of Health and Social Affairs (DOHSA), Chuuk Women's Council (CWC)

Major achievements:

- Reviewed and updated national guidelines on HIV, STIs and TB to align with the latest WHO guidelines.
- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- Improved TB treatment success rate through capacity building of health workers on DOTS treatment, as well as funding of positions.
- Provided free treatment to people with MDR-TB.
- Built capacity of health workers and representatives from CWC by supporting participation at regional TB and clinicians capacity building forums.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- Supported delivery of HIV and STI services, including testing at antenatal clinics, provision of ARVs for all people living with HIV, and distribution of condoms and lubricants through DOHSA-run HIV Counselling and Testing Centers. Furthermore, CWC distributed condoms and lubricants to community members as part of outreach efforts, including to key populations.
- In 2017, CWC disseminated HIV prevention packages to 84 men who have sex with men and transgender people, and to 95 sex workers. CWC also conducted 55 voluntary HIV tests in the community, with all knowing their results and no positive cases found.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
DOHSA			\$343,663.00	\$188,793.12	\$343,663.00	\$188,793.12
CWC			\$42,430.00	\$29,591.05	\$42,430.00	\$29,591.05
Total			\$386,093.00	\$218,384.17	\$386,093.00	\$218,384.17

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$12,493.67	\$8,987.88	\$21,481.55
Condoms & Lubricants		\$2,732.55	\$5,498.60	\$8,231.15
HIV/STI/TB Lab Reagents	\$255.00	\$10,687.10	\$46,458.35	\$57,400.45
IEC Materials & Media Campaign		\$488.48	\$430.00	\$918.48
IT Equipments & Printer			\$790.00	\$790.00
Medical Equipments	\$4,575.00		\$81,476.50	\$86,051.50
Other Consumables, Disposables		\$718.64		\$718.64
Other Items		\$329.76	\$2,304.70	\$2,634.46
Pharmaceuticals		\$1,004.74	\$2,658.95	\$3,663.69
Total	\$4,830.00	\$28,454.94	\$148,604.98	\$181,889.92

Performance against key programme indicators, Federated States of Micronesia

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	67%	100%
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	44 *	141	133
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	11 *	34	31
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	100%	34	90%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	0	100%	86%
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	96%	100%	95%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	98%	100%	95%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	100%	N/A	100%
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	100%	N/A	100%
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	70%	55%	42%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	45 *	147	139
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	11 *	36	32
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	87%	81%	90%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	100%	94%	86%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	87%	66%	80%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	N/A	N/A	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	100%	0%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Kiribati

Ministry of Health and Medical Services (MOHMS)

Major achievements:

- Built capacity on HIV and TB outreach through a series of trainings for clinicians, nurses and key populations (female sex workers, men who have sex with men and transgender people) peer outreach workers.
- Health workers, including laboratory and antenatal clinic staff, trained on the SD Duo rapid diagnostic test for HIV and syphilis. The pilot phase has been completed and the tool is now being rolled out country-wide.
- Supported a review of the Kiribati National HIV and STI Policy that produced recommendations to be included in the newly updated version in 2017.
- Reviewed and updated national guidelines on HIV testing services, ART, STIs, PPTCT and TB to align with the latest WHO guidelines.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- Active case finding outreach for HIV and TB conducted in hot spot areas.
- HIV and TB monitoring and evaluation visit to outer islands conducted to improve data collection and upgrade clinical skills.
- Developed a TB patient empowerment and support group programme to strengthen awareness and improve treatment adherence.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOHMS	\$70,287.80	\$70,231.00	\$177,653.75	\$139,348.75	\$274,451.12	\$209,579.75

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$9,254.50	\$24,330.79	\$33,585.29
Condoms & Lubricants		\$9,935.04		\$9,935.04
Furniture & Fittings			\$2,026.26	\$2,026.26
HIV/STI/TB Lab Reagents	\$427.76	\$23,906.50	\$59,011.07	\$83,345.33
IEC Materials & Media Campaign		\$394.24	\$2,480.00	\$2,874.24
IT Equipments & Printer		\$790.00	\$10,290.40	\$11,080.40
Medical Equipments		\$17,500.00	\$150,407.79	\$167,907.79
Other Consumables, Disposables		\$1,176.60	\$6,281.00	\$7,457.60
Other Items		\$568.62	\$4,027.06	\$4,595.68
Pharmaceuticals		\$1,664.89	\$13,150.57	\$14,815.46
Motor Vehicles, Boats & Engines			\$72,852.76	\$72,852.76
Total	\$427.76	\$65,190.39	\$344,857.70	\$410,475.85

Performance against key programme indicators, Kiribati

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	67%	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	251 *	469	354
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	148 *	165	175
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	83%	83%	83%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	N/A	N/A	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	71%	64%	86%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	71%	50%	91%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	N/A	100%	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	100%	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	25%	30%	100%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	285 *	515	388
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	168 *	181	192
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	83%	88%	89%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	86%	93%	91%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	33%	42%	36%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	17%	100%	100%
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	N/A	0%
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Republic of the Marshall Islands

Ministry of Health (MOH)

Major achievements:

- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- With the support of several agencies including UNDP, WHO, the US CDC and the Pacific Islands Health Officer Association, conducted a mass screening for TB as well as Hansen's disease (leprosy), diabetes and high blood pressure. A mobile x-ray machine was supplied and training provided. As a result, tracking and management of patients was strengthened and significant increases in new cases identified.
- Reviewed and updated national guidelines on HIV, STIs and TB to align with the latest WHO guidelines.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- Built capacity of health workers by supporting participation at regional HIV and TB capacity building forums.
- Supported delivery of HIV and STI services, including testing at antenatal clinics and provision of ARVs for all people living with HIV.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOH	\$285,509.00	\$158,037.00	\$176,341.00	\$156,344.16	\$445,887.00	\$314,381.16

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$11,006.67	\$10,500.00	\$21,506.67
Condoms & Lubricants		\$2,506.32	\$4,109.48	\$6,615.80
HIV/STI/TB Lab Reagents	\$422.00	\$14,556.10	\$29,595.89	\$44,573.99
IEC Materials & Media Campaign		\$394.24	\$40.00	\$434.24
Medical Equipments		\$62,200.00	\$35,000.00	\$97,200.00
Other Consumables, Disposables		\$647.50		\$647.50
Other Items		\$1,752.66	\$1,224.20	\$2,976.86
Pharmaceuticals		\$950.84	\$1,503.67	\$2,454.51
Total	\$422.00	\$94,014.33	\$81,973.24	\$176,409.57

Performance against key programme indicators, Republic of the Marshall Islands

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	0%	0%
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	159 *	327	375
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	51 *	153	144
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	88%	83%	83%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	N/A	N/A	100%
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	N/A	100%	75%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	NA	90%	67%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	N/A	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	86%	100%	100%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	86 *	180	206
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	28 *	84	79
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	93%	82%	75%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	88%	83%	83%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	98%	91%	92%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	N/A	100%	100%
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Nauru

Ministry of Health and Medical Services (MOHMS)

Major achievements:

- As part of efforts to improve the quality of TB laboratory services, an on-site supervisory evaluation of the National Laboratory services was conducted by the Pacific Paramedical Training Centre. A report with recommendations for lab improvements was developed and submitted.

- Reviewed and updated national guidelines on HIV, STIs and TB to align with the latest WHO guidelines.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- Built capacity of health workers through support to participation at the regional HIV capacity building forum.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOHMS	\$19,137.00		\$13,670.50		\$32,807.50	

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$4,249.00	\$4,980.00	\$9,229.00
Condoms & Lubricants			\$302.00	\$302.00
HIV/STI/TB Lab Reagents		\$1,129.20	\$2,597.22	\$3,726.42
IEC Materials & Media Campaign		\$150.00	\$1,749.09	\$1,899.09
Other Items			\$893.00	\$893.00
Pharmaceuticals		\$241.85	\$32.10	\$273.95
Total		\$5,770.05	\$10,553.41	\$16,323.46

Performance against key programme indicators, Nauru

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	NA	N/A	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	NA	93	83
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	NA	74	83
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	NA	100%	70%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	NA	N/A	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	NA	62%	NA
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	NA	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	NA	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	NA	53%	NA
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	NA	N/A	NA
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	NA	N/A	NA
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	NA	0	NA
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	NA	10	9
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	NA	8	9
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	NA	78%	70%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	NA	100%	70%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	NA	90%	0%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	NA	N/A	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	NA	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	NA	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	NA	100%	0%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

Niue

Department of Health (DOH)

Major achievements:

- Increased awareness on HIV, STIs and TB amongst the public and target audiences through a collaborative effort by the Department of Health with nongovernmental and community organizations such as the Women's Council, Youth Council, as well as other government ministries. Activities have been conducted since February 2016.
- As part of efforts to improve the quality of TB laboratory services, an on-site supervisory evaluation was conducted by the Pacific Paramedical Training Centre. A report with recommendations for lab improvements was developed and submitted.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- UNDP provided technical assistance to Niue Programme Coordinator on how to engage target key populations. As a result, a very first meeting was conducted in Dec 2017 by Niue Chief Public Health Officer and members of the LGBTQ community, which served as a starting point of their collaboration and partnership.
- Improved capacity of health workers by supporting procurement of computers and office equipment for the Niue Health Programme Coordinator in 2016.
- Reviewed and updated national guidelines on HIV and STIs to align with the latest WHO guidelines.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
DOH	\$32,064.00	\$3,508.00	\$38,416.03	\$14,184.94	\$70,480.03	\$17,692.94

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$5,646.00		\$5,646.00
Condoms & Lubricants		\$99.32	\$57.88	\$157.20
HIV/STI/TB Lab Reagents		\$977.80	\$881.27	\$1,859.07
IEC Materials & Media Campaign		\$173.56	\$15.00	\$188.56
IT Equipments & Printer		\$1,497.07	\$1,497.07	\$2,994.14
Medical Equipments			\$11,482.82	\$11,482.82
Other Consumables, Disposables		\$1.99		\$1.99
Other Items		\$718.42	\$667.30	\$1,385.72
Pharmaceuticals		\$109.42	\$29.70	\$139.12
Total		\$9,223.58	\$14,631.04	\$23,854.62

Performance against key programme indicators, Niue

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	NA	N/A	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	NA	N/A	N/A
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	NA	0	N/A
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	NA	0	N/A
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	NA	0	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	NA	0%	0%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	NA	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	NA	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	NA	72%	53%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	NA	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	NA	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	NA	0	N/A
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	NA	0	0
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	NA	0	0
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	NA	N/A	N/A
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	NA	N/A	N/A
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	NA	N/A	N/A
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	NA	N/A	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	NA	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	NA	N/A	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	NA	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

Impact stories

“It’s all about the health of my people”

Advocates for HIV prevention in the Pacific talk about their motivations and challenges



Chuuk – Sincera Fritz, Chuuk Women’s Council

“These groups [key populations] face so many challenges—rape and violence, social stigma, discrimination, both by family members and the community. Many feel they are left out, and they think that they are useless. I give them encouragement. And I educate them to change their risky behaviour.”

“Most of these people don’t want to go to the hospital because they fear they’ll face stigma and discrimination. Instead they prefer to come to our centre where we can provide counselling and referrals to a more friendly, accepting clinic.”

“I give them my time and let them know there is someone that they can speak with. They can open up with me to share their frustrations and anger. I really want to help them.”

Tonga – Agabe Tuinukuafe, Tonga Leitis Association

“After the first arrival of HIV in Tonga in 1987 there was a lot of labelling and finger pointing targeting the LGBT community because the first person with HIV was a gay man. That’s why a small group of people came together and formed TLA in 1992—to stop the stigma and discrimination, especially towards men who have sex with men and transgender people but also other key affected populations. Now, TLA is an official, registered NGO.”

Samoa – A’aone Tanumafili Taveuveu, Ministry of Health

“I am passionate about my job. I want to be able to look back at my career and see that I’ve done something, that I’ve made a difference. My focus is to look to the future—the young generation. I think this is what drives me.”

“It’s all about the health of my people... We need to make sure that our people are healthy, especially the key populations. They are the most vulnerable. And at the end of the day, we don’t want to leave anyone behind.”

[Read more](#)



Health agencies collaborate to boost response to dual crisis of diabetes and TB in Ebeye

With 466 cases identified per 100,000 people, the Republic of the Marshall Islands (RMI) has one of the highest TB prevalence in the world. Despite many decades of efforts to eradicate the devastating disease, it has continued to spread in the overcrowded atoll communities fueled by poor nutrition, high rates of diabetes, substandard housing and poor health seeking behaviours. Ebeye – the most populous island in the Kawajalein Atoll in RMI – also faces a dual epidemic of non-communicable diseases such as diabetes. In fact, diabetes is the number one public health problem and the leading cause of premature mortality in the RMI, affecting over 20 percent of the adult population.

To help bring the situation under control in RMI, the Ministry of Health, supported by several agencies including UNDP, WHO, the US CDC and the Pacific Islands Health Officer Association, embarked on a mass screening and treatment programme in early 2017. The screening, which also checked for Hansen's disease (leprosy), diabetes and high blood pressure, was preceded by a pre-registration phase of all residents through a fingerprint digitizing system.

As a result, tracking and management of patients improved while the approach also provided opportunities for weight checkups and health counselling. Specialist doctors, epidemiologists, nurses and volunteers from RMI and abroad participated in the screening and subsequent case management. New cases identified resulted in the near doubling of the usual annual caseload of around 50.

[Read more](#) [Watch the video](#)



Palau

Ministry of Health (MOH)

Major achievements:

- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- Development of a strategy to better manage TB/diabetic patients.
- Reviewed and updated national guidelines on HIV, STIs and TB to align with the latest WHO guidelines.
- Provided financial and technical support to strengthen HIV and STI prevention targeting sex workers, specifically the Ladies in the Entertainment Business programme.

- Supported delivery of HIV and STI services, including testing at antenatal clinics and provision of ARVs for all people living with HIV.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- Built capacity of health workers by supporting participation at regional HIV and TB capacity building forums.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOH	\$47,343.00	\$19,770.00	\$155,834.37	\$47,130.88	\$177,574.37	\$66,900.88

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$16,280.67	\$16,995.25	\$33,275.92
Condoms & Lubricants		\$243.71	\$629.52	\$873.23
HIV/STI/TB Lab Reagents		\$2,032.20	\$11,569.42	\$13,601.62
IEC Materials & Media Campaign		\$3,000.00	\$3,590.00	\$6,590.00
IT Equipments & Printer		\$1,301.50		\$1,301.50
Other Consumables, Disposables		\$450.00		\$450.00
Other Items		\$1,037.60	\$1,617.40	\$2,655.00
Pharmaceuticals		\$505.99	\$889.14	\$1,395.13
Motor Vehicles, Boats & Engines			\$72,852.76	\$72,852.76
Total		\$24,851.67	\$108,143.49	\$132,995.16

Performance against key programme indicators, Palau

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	N/A	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	33 *	129	112
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	22 *	96	107
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	33%	86%	100%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	N/A	100%	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	100%	80%	84%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	98%	79%	81%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	N/A	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	60%	60%	60%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	6 *	23	20
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	4 *	17	19
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	50%	86%	90%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	33%	86%	100%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	100%	91%	100%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	N/A	N/A	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Samoa

Ministry of Health (MOH), Samoa Fa'afine Association (SFA), Samoa Family Health Association (SFHA)

Major achievements:

- Since 2015, have strengthened partnership collaboration between MOH, the National Health Service, SFHA and SFA to: advocate and promote the rights of people living with HIV and key populations; provide clinical, financial and social support to people living with HIV; improve counselling and testing for HIV, STIs and TB; and improve integration of programmes to include HIV/STIs and TB, for instance NCD programmes and services.
- Assisted MOH in engaging the Samoa Teen Challenge Organization in advocating and promoting awareness of gender-based violence issues and HIV, STIs and TB.
- Supported the finalization of the Samoa HIV/AIDS, STI and TB M&E Manual in 2017, including providing comments and financial assistance for the publishing and launch of the manual.
- Conducted a review of the former National HIV Policy, which was used to inform updates to the new National HIV Policy for 2017-2022.
- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- Raised awareness on HIV, STIs and TB through mass media through an innovative public-private partnership with Digicel, MOH, SFHA and the National Health Service. Data collection was also conducted through online call surveys to inform future programming.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOH	\$65,275.00	\$47,620.00	\$124,017.76	\$140,081.80	\$174,528.00	\$187,701.80
SFA			\$44,214.26	\$31,580.05	\$44,214.26	\$31,580.05
SFHA			\$43,231.26	\$31,129.33	\$43,231.26	\$31,129.33
Total	\$65,275.00	\$47,620.00	\$211,463.28	\$202,791.18	\$261,973.51	\$250,411.18

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$7,304.50	\$14,100.09	\$21,404.59
Condoms & Lubricants		\$3,784.39	\$7,644.12	\$11,428.51
Furniture & Fittings		\$5,118.20		\$5,118.20
HIV/STI/TB Lab Reagents	\$760.50	\$21,803.73	\$92,162.13	\$114,726.36
IEC Materials & Media Campaign		\$1,648.54	\$25,885.64	\$27,534.18
IT Equipments & Printer		\$790.00	\$790.00	\$1,580.00
Medical Equipments		\$17,000.00	\$35,000.00	\$52,000.00
Other Consumables, Disposables		\$450.00		\$450.00
Other Items		\$1,297.00	\$3,045.26	\$4,342.26
Pharmaceuticals		\$7,778.96	\$15,348.09	\$23,127.05
Total	\$760.50	\$66,975.32	\$193,975.33	\$261,711.15

Performance against key programme indicators, Samoa

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	N/A	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	8 *	7	15
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	5 *	5	7
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	33%	100%	80%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	N/A	N/A	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	97%	100%	91%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	99%	100%	91%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	N/A	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	100%	100%	100%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	21 *	13	30
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	15 *	10	14
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	52%	95%	85%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	47%	100%	80%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	NA	69%	93%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	0%	N/A	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	100%	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Tonga

Ministry of Health (MOH), Tonga Leitis Association (TLA), Tonga Family Health Association (TFHA)

Major achievements:

- Built the capacity of clinicians, nurses and peer outreach workers on HIV, TB and key populations through training workshops, followed by a series of outreach programmes initiated at prisons, hot spots, ANCs, diabetic clinics and with key population communities (including young key populations).
- Health workers, including laboratory and antenatal clinic staff, trained on the SD Duo rapid diagnostic test for HIV and syphilis. The pilot phase has been completed and the tool is now being rolled out country-wide.
- Reviewed and updated national guidelines on HIV testing services, ART, STIs, PPTCT and TB to align with the latest WHO guidelines.
- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- Development of a new national HIV, STIs and TB database that is linked to the national health information system.
- Conducted a national level training on TB case management and introduced new recording and reporting registers and forms.
- As part of efforts to improve the quality of TB laboratory services, an on-site supervisory evaluation of the National Laboratory services was conducted by the Pacific Paramedical Training Centre. A report with recommendations for lab improvements was developed and submitted.
- TLA conducted HIV and STI prevention, awareness and outreach activities with key population communities, including distributing condoms and lubricants at bars, nightclubs and youth drop-in centres; providing demonstrations for safer sex; and conducting testing.
- Raised awareness of the public and target groups through a TV and radio campaign.
- Development and launch of a new TLA website, which contains information on HIV and STIs prevention, testing, treatment and care services.
- Strengthened the referral system of TFHA outreach activities to link directly to the MOH as part of the newly introduced point of care HIV and STIs testing.
- Raised awareness on HIV, STIs and TB through mass media through an innovative public-private partnership with Digicel and MOH.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOH	\$123,887.00	\$44,938.00	\$125,368.73	\$155,015.46	\$224,178.92	\$199,953.46
TLA			\$33,618.73	\$31,949.71	\$33,618.73	\$31,949.71
TFHA			\$29,741.05	\$30,694.75	\$29,741.05	\$30,694.75
Total	\$123,887.00	\$44,938.00	\$188,728.51	\$217,659.92	\$287,538.70	\$262,597.92

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$7,826.00	\$12,241.63	\$20,067.63
Condoms & Lubricants		\$910.65	\$1,447.00	\$2,357.65
HIV/STI/TB Lab Reagents		\$16,385.70	\$37,760.54	\$54,146.24
IEC Materials & Media Campaign		\$394.24	\$4,596.54	\$4,990.78
IT Equipments & Printer		\$790.00	\$790.00	\$1,580.00
Medical Equipments		\$17,000.00	\$17,500.00	\$34,500.00
Other Consumables, Disposables		\$138.30		\$138.30
Other Items		\$1,087.42	\$5,497.70	\$6,585.12
Pharmaceuticals		\$988.24	\$502.72	\$1,490.96
Total		\$45,520.55	\$80,336.13	\$125,856.68

Performance against key programme indicators, Tonga

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	N/A	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	3 *	9	14
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	1 *	5	7
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	100%	83%	100%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	N/A	N/A	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	67%	96%	98%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	76%	96%	98%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	N/A	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	0%	25%	35%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	3 *	9	14
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	2 *	5	7
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	100%	93%	100%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	100%	83%	100%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	100%	100%	100%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	N/A	N/A	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Tuvalu

Ministry of Health (MOH), Tuvalu Family Health Association (TFHA)

Major achievements:

- Built the capacity of clinicians, nurses and community volunteers on outreach work and knowledge of HIV and TB through training workshops.
- Reviewed and updated national guidelines on HIV testing services, ART, STIs, PPTCT and TB to align with the latest WHO guidelines. Government endorsement is expected in 2018.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.

- TB and HIV monitoring and evaluation visit to outer islands conducted to improve data collection and upgrade clinical skills.
- Strengthened contact tracing among health workers through training workshops.
- Conducted community outreach amongst vulnerable populations, namely youths, key populations and prisoners.
- Supported TFHA in recruiting and conducting trainings for HIV peer educators.
- Conducted outreach to outer islands to raise awareness of HIV and STIs, and provided voluntary counselling and testing services.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOH	\$65,275.00	\$27,540.00	\$48,550.19	\$57,143.86	\$150,561.19	\$84,683.86
TFHA			\$23,226.05	\$14,409.39	\$23,226.05	\$14,409.39
Total	\$65,275.00	\$27,540.00	\$71,776.25	\$71,553.25	\$173,787.25	\$99,093.25

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$9,483.50	\$13,171.72	\$22,655.22
Condoms & Lubricants		\$158.19	\$173.64	\$331.83
Furniture & Fittings		\$1,638.78		\$1,638.78
HIV/STI/TB Lab Reagents		\$2,822.00	\$9,392.92	\$12,214.92
IEC Materials & Media Campaign		\$197.12	\$1,865.00	\$2,062.12
IT Equipments & Printer		\$2,363.23		\$2,363.23
Medical Equipments		\$17,500.00	\$63,976.50	\$81,476.50
Other Consumables, Disposables		\$507.21		\$507.21
Other Items		\$229.51	\$2,240.30	\$2,469.81
Pharmaceuticals		\$785.54	\$22.80	\$808.34
Total		\$35,685.08	\$90,842.88	\$126,527.96

Performance against key programme indicators, Tuvalu

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	N/A	N/A
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	136 *	198	28
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	81 *	119	178
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	47%	78%	89%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	N/A	N/A	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	NA	99%	100%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	NA	100%	99%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	N/A	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	NA	0%	NA
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	15 *	20	23
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	9 *	12	18
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	47%	90%	90%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	47%	78%	89%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	100%	85%	9%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	100%	100%	100%
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	N/A	N/A
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	0	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Vanuatu

Ministry of Health (MOH), Save the Children (STC), Vatu Mauri Consortium (VMC)

Major achievements:

- Reviewed and updated national guidelines on HIV, STIs and TB to align with the latest WHO guidelines.
- As part of efforts to improve the quality of TB laboratory services, an on-site supervisory evaluation of the National Laboratory services was conducted by the Pacific Paramedical Training Centre. A report with recommendations for lab improvements was developed and submitted.
- Conducted TB hot spot mapping and increased active case finding interventions.
- Strengthened capacity of health workers on HIV, STIs and TB and outreach through regular training and refresher workshops.
- Capacity strengthened of health workers working on HIV and STIs through a mentorship programme by ASHM-OSSHM.
- GeneXpert machine provisioned and trainings provided for health workers to boost diagnostic capacity and improve the TB case detection rate.
- Strengthened capacity of local community group leaders from throughout Vanuatu through a national workshop on sexual orientation and gender identity

and expression, with support from the Pacific Sexual Diversity and Gender Network, V Pride and the Ministry of Health.

- National consultation organized on gender-based violence towards men who have sex with men and transgender people to collect data on real lived experiences of the community to inform advocacy and programming.
- Reported zero cases of mother to child transmission of HIV from 2015-2017.
- Provided HIV prevention packages to 30 men who have sex with men, and HIV testing services to 18 men who have sex with men.
- Raised awareness on HIV, STIs and TB through mass media through an innovative public-private partnership with Digicel and MOH. Data collection was also conducted through online call surveys to inform future programming.
- Data generated to inform programme design through a multi-country mapping and behavioural study focusing on HIV and STI risk vulnerability for key populations in 2016, including key populations size estimates.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
MOH	\$257,256.00	\$72,867.00	\$440,977.99	\$364,797.74	\$501,515.60	\$437,664.74
STC			\$507,832.06	\$567,755.67	\$507,832.06	\$567,755.67
VMC			\$218,213.15	\$123,144.36	\$218,213.15	\$123,144.36
Total	\$257,256.00	\$72,867.00	\$1,167,023.21	\$1,055,697.77	\$1,227,560.81	\$1,128,564.77

Procurement

Classification	2015	2016	2017	Total
Capacity Development & Building		\$12,290.50	\$16,843.13	\$29,133.63
Condoms & Lubricants		\$18,438.61	\$30,502.76	\$48,941.37
HIV/STI/TB Lab Reagents	\$427.76	\$16,727.20	\$41,477.79	\$58,632.75
IEC Materials & Media Campaign		\$738.61	\$40,939.37	\$41,677.98
IT Equipments & Printer		\$2,719.80	\$1,140.00	\$3,859.80
Medical Equipments		\$17,500.00	\$104,476.50	\$121,976.50
Other Consumables, Disposables		\$894.75	\$242.04	\$1,136.79
Other Items		\$852.93	\$2,926.30	\$3,779.23
Pharmaceuticals		\$1,765.33	\$8,980.80	\$10,746.13
Total	\$427.76	\$71,927.73	\$247,528.69	\$319,884.18

Performance against key programme indicators, Vanuatu

Indicator Description	2015	2016	2017
Outcome Indicators			
HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	N/A	N/A	100%
TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	16 *	35	31
TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	5 *	14	16
TB O-2b: Treatment success rate - bacteriologically confirmed TB cases	87%	82%	98%
TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	N/A	N/A	N/A
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	100%	65%	43%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	N/A	N/A
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	N/A	N/A
PMTCT-1: Percentage of pregnant women who know their HIV status	79%	43%	36%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	100%	N/A	N/A
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	N/A	N/A
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	67%	83%	67%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	44 *	100	91
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	15 *	42	47
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	80%	73%	88%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	87%	82%	98%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	43%	51%	70%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	N/A	100%	N/A
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	N/A	N/A	100%
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	100%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	100%	100%	100%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Fiji Network of People Living with HIV (FJN+)

Major achievements:

- A multi-county Stigma Index study was implemented in seven countries and a summary of findings was released in February 2018. The study provided valuable data on the real lived experiences of people living with HIV and will inform programmes, interventions and policies to ensure more effective HIV responses in the region. The findings will also be an important advocacy tool for networks of people living with HIV and civil society organizations working with groups that are most vulnerable to HIV. Country level reports have been submitted to each participating country.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
FJN+		\$127,730.15	\$77,751.45	\$127,730.15	\$77,751.45	\$103,208.69

Pacific Sexual and Gender Diversity Network (PSGDN)

Major achievements:

- Strengthened overall organizational governance, planning and advocacy through a number of initiatives, including development of a monitoring and evaluation framework, development of an operational policies and procedures manual, revising the organization's Strategic Plan for 2014-2019, and organizing an annual general meeting and regional board meeting in 2017 to facilitate approval of a new constitution, governance structure and secretariat organogram.
- Built capacity of PSGDN members to bolster the community response to HIV in the Pacific through a regional workshop on monitoring and evaluation frameworks and theory of change.
- Strengthened capacity of local community group leaders from throughout Vanuatu by co-facilitating a workshop on sexual orientation and gender identity and expression, in collaboration with V Pride and the Ministry of Health.
- Facilitated knowledge exchange and networking through participation at key regional and international forums, including at the Australasian HIV and AIDS Conference, 6-9 November 2017 in Canberra, Australia and the APCOM Rights, Resources & Resilience Asia Pacific Summit in Bangkok 12-17 November.

Budget vs. actual

SR	2016		2017		2015-2017	
	Allocation	Actual	Allocation	Actual	Allocation	Actual
PSGDN			\$361,364.60	\$188,520	\$361,364.60	\$188,520



Tonga Leitis' Association in partnership with the Ministry of Health distributes condoms and lubricants, targeting key populations at hotspot locations.



The programme has enabled a small team from Chuuk Women's Council to carry out much needed outreach to men who have sex with men, transgender people and sex worker communities.



The Family Health and Communicable Disease Units of the Palau Bureau of Public Health conduct outreach sessions on reproductive health, HIV and STIs at the Palau Community College.



IEC materials are distributed by the Ministry of Health of the Cooks Islands to people as part of a voluntary testing and counselling programme on the mainland of Rarotonga.

REGIONAL ACTIVITIES AND COOPERATION

Given that diseases do not respect borders, the most effective response at times can be one that brings together several countries from across a region. To achieve this, the programme has leveraged the expertise of civil society, academia, the private sector, government, UN and other development partners. A comprehensive technical assistance package has also been provided to the 11 programme countries through a regional team composed of WHO, SPC, UNICEF, UNAIDS and ASHM-OSSHHM. Such engagement and cooperation has not only increased regional coordination, but enabled more effective strengthening of capacity of individuals and institutions to carry out HIV and TB responses.

Some of the key regional activities and partnerships are highlighted below.

Enhancing diagnostics capacity for HIV, STIs, TB and co-morbidities

To effectively control HIV and TB in the Pacific there is a need to strengthen overall health systems. This includes, equipping medical professionals with the required tools and skills to carry out diagnostic assessments.

In 2017, a new diagnostic test for HIV and syphilis, known as the **Standard Diagnostics Bioline HIV/Syphilis (or SD Duo) test**, was [piloted in five countries](#) (Kiribati, Palau, Samoa, Tonga and Vanuatu) and a full roll-out is planned for 2018. SD Duo is a recently developed rapid diagnostic test that can detect HIV and syphilis infection using finger prick blood or serum. SD Duo has been recommended by the Pacific Islands Regional Country Coordinating Mechanism for use as a screening tool in Pacific island countries because of concerns over high prevalence of syphilis and low HIV and syphilis testing amongst ANC attendees and key populations. The test is also a cost-effective intervention, amounting to about \$1.98 per test. This is cheaper than the existing diagnostic test, requires no sophisticated equipment and can be performed in laboratories with limited facilities as well as in non-laboratory settings. It will introduce point of care testing, resulting in a much quicker turnaround, vastly reduced 'loss to follow-up' and improved treatment rates. A regional workshop was held on 27–28 June 2017 in Nadi, Fiji to train laboratory and antenatal clinic staff from the five countries on SD Duo. The pilot focused on patients attending ANCs and helped to identify challenges to implementation and logistics, contributing to ensuring a successful regional roll-out.

To address persistently high rates of TB, the programme is introducing a mass screening initiative in Chuuk, Kiribati, Tuvalu and Vanuatu with the goal of significantly reducing incidence. The initiative uses the **GeneXpert** diagnostic tool in conjunction with **portable digital x-ray machines**. The programme has supported the national TB programmes by procuring the much needed diagnostics, medicines and commodities, and providing laboratory support and staffing. As of the end of 2017, the portable x-ray machines have been delivered to each of the countries and is expected to be operational following in-country trainings planned for March and April 2018. Technical assistance partner WHO will be providing country support on the planning and implementation of the mass screenings.

A total of 13 sets of 4 module laptop-based **GeneXpert** instruments have been supplied to Cooks Islands (1), Kiribati (2), Federated States of Micronesia (1), Republic of Marshall Islands (1), Samoa (3), Tonga (1), Tuvalu (1) and Vanuatu (3) over the grant period to enable these countries to test for TB and rifampicin (RIF) resistance using MTB-RIF cartridges, viral load for HIV patients using Xpert HIV-VL cartridges, and chlamydia and gonorrhoea using Xpert CT/NG cartridges and urine collection kits.

To ensure that GeneXpert instruments are successfully installed and properly operated, on-site trainings were provided for laboratory technicians in all of the eight countries in 2016 and 2017, along with information sessions to inform clinicians, health care workers and National Tuberculosis Programme staff of the instrument's capabilities. Highly skilled trainers from Cepheid, the supplier of GeneXpert, were sent to conduct three day 'Master Class' trainings for groups of 6-15 participants, who were subsequently awarded certificates of completion and qualified to train other laboratory personnel at the national level.

Strengthening health systems to better control HIV, STIs and TB

Following a comprehensive needs assessment, a mentorship initiative – the **Pacific Sexual Health Worker Capacity Building Programme** – was developed by ASHM-OSSHHM in 2017. The initiative has provided the opportunity for health workers who supply HIV, STI or TB services in the 11 programme countries to receive mentoring and support to maintain up-to-date knowledge in HIV clinical care, assist local health care workers manage more complex cases, and build valuable professional relationships with mentors and health care professionals from around the region. The clinical

mentoring model is also designed to facilitate South-South collaboration between Pacific countries. As of the end of 2017, a pool of mentors has been established, consisting of seven Fiji-based clinicians and supported by ASHM mentors based in Australia and Papua New Guinea. The initiative also involved updating training packages including one on transgender health developed in partnership with PSGDN, updating and developing HIV, STI and SRH resources and tools, and establishing a practical communication mechanism. The communication channels decided upon after consultation was email and telephone with a view to incorporating technologies such as webinars and online forums when reliable internet infrastructure is more widely available. A summary report of the initiative is [available online](#).

On-site supervisory evaluations of the national TB laboratories was conducted by the Pacific Paramedical Training Centre in eight countries (Cook Islands, Kiribati, Nauru, Niue, Samoa, Tonga, Tuvalu and Vanuatu) in 2017. A report with recommendations for lab improvements was developed and submitted to each country. The initiative is part of efforts to improve the quality of TB laboratory services through external quality assessments and promote universal and equitable access to quality diagnosis and appropriate treatment of TB, MDR-TB, TB/DM and TB/HIV patients across the region. The on-site evaluation involved an audit of operational requirements expected to be met in a TB laboratory and is designed along similar quality principles expressed in international laboratory accreditation standards. The evaluation identified gaps in TB services provided and revealed the state of on-site analysis. A summary report of the activity is [available online](#).

Two large **regional TB-related capacity building workshops** were organized by the programme in 2017. On 21-25 August 2017, a regional training of trainers workshop was organized in Nadi, Fiji with 25 participants from 10 countries (Cook Islands, Fiji, Federated States of Micronesia, Kiribati, Republic of the Marshall Islands, Niue, Samoa, Tonga, Tuvalu and Vanuatu), including TB clinicians and programme managers. The training was organized by UNDP and WHO and covered all aspects of drug susceptibility, drug resistance and comorbidities, as well as M&E, programmatic management of drug resistant TB, as well as TB in children. Earlier the same month, a comprehensive training for TB laboratory technicians from the countries was organized by UNDP, the Fiji Global Fund grant and SPC from 7-11 August 2017, also in Nadi, Fiji. The training addressed aspects of improving laboratory functions and quality assurance, on-site evaluation, GeneXpert training and International Air Transport Association certification and accreditations. A total of 25 participants from nine countries (Cook Islands, Fiji, Federated States of Micronesia, Kiribati, Palau, Samoa, Tonga, Tuvalu and Vanuatu) attended.



A laboratory technician taking part in the on-site evaluations of national TB laboratories.



A laboratory technician prepares to load the Xpert MTB/RIF cartridge during GeneXpert trainings.



The programme has supported community CSOs working on HIV throughout the region as part of its efforts to improve prevention, treatment and care interventions.



Public health workers from the Ministry of Health in Samoa take part in an event for the 'T3: Talk it, Test it, Treat it' mass media campaign to address HIV, STIs and TB.

Recently, the WHO released new guidelines for countries, sharing the latest WHO recommendations for the management of HIV, STIs and TB. A comprehensive technical assistance package is being delivered to the 11 programme countries to **align all national guidelines with the new WHO guidelines**. This is done through a regional team approach that started in 2016. The regional team is composed of WHO, SPC, UNICEF and UNAIDS. As of the end of 2017, the national guidelines have been updated for all 11 countries, with government endorsement achieved for Cook Islands, Kiribati, Tonga and Vanuatu.

Strengthening communities and their involvement in the response

Across the region, there is a need to strengthen community organizations working with key populations and elevate their involvement in the HIV response. The programme has made efforts to strengthen the capacity of national CSOs as well as regional organizations such as PSGDN and FJN+, with a view to having both serve as mentors and trainers to individual country CSOs or support groups. In 2017, the programme provided support to PSGDN to strengthen its organizational governance, planning and advocacy through a number of initiatives, including development of a monitoring and evaluation framework, development of an operational policies and procedures manual, revising the organization's Strategic Plan for 2014-2019, and support for an annual general meeting and regional board meeting to facilitate approval of a new constitution, governance structure and secretariat organogram. PSGDN subsequently passed on knowledge to community SRs through a [regional workshop](#) on 26-30 June 2017 with over 35 representatives of community groups from 13 Pacific island countries working on issues related to the human rights, health and inclusion of people of diverse sexual orientation and gender identity.

Innovative interventions

In March 2017, an innovative mass media campaign to raise awareness and promote prevention, treatment and care services for HIV, STIs and TB was [launched](#) involving a public-private partnership between UNDP, Digicel, the Ministries of Health in Samoa, Tonga and Vanuatu, and other partners. As part of the campaign, text messages and digital ads on Digicel's Loop media network were delivered and directed people to landing webpages with more information on prevention and where to go for testing, treatment, care and support services. To ensure target audiences were optimally reached, the content was disseminated in both English and local languages and to

strategic geographic locations and demographics. In Vanuatu, the TB campaign reached over 194,000 subscribers and had over 5,700 visitors to the landing page (English, Bislama) over a two week period. In Samoa, over 100,000 subscribers were reached with HIV/STI, TB and teen pregnancy awareness messages. The TB campaign landing page (English, Samoan) attracted over 5,300 visitors over five weeks. In Tonga, the TB campaign involved weekly SMS delivery to 20,000 subscribers, and the landing page attracted over 23,000 views.

Promoting cross-country learning

The island countries of the western Pacific face some unique challenges for the provision of health services, including socio-economic disparities, living conditions, poor diet, lack of public health resources, geographically dispersed populations, and in some countries an unsupportive legal and policy environment. Therefore, a key component of the programme has been to facilitate cross-country and South-South learning to match the unique needs of the region. To achieve this, several regional forums have been organized: the [Multi-Country Western Pacific Programme Sub-Recipients Meeting](#), organized by UNDP in Nadi, Fiji on 21-23 November 2017; the [Eighth TB Control Meeting for the Pacific Islands](#), organized by WHO and UNDP in partnership with the Fiji Ministry of Health & Medical Services in Nadi, Fiji on 22-24 November 2016; and the Pacific HIV Forum, organized by UNDP in Suva, Fiji on 14-18 November 2016.

Strategic information and creating an enabling legal environment

A key outcome of the grant was the creation of a regional body of strategic knowledge. This strategic knowledge base is invaluable as an advocacy tool for community-led policy reform efforts across the region. Two major regional studies, with country level components, were undertaken through the programme.

The [Pacific People Living with HIV Stigma Index](#) study was released on 28 February 2018. The study found that people living with HIV in the Pacific islands are experiencing high levels of stigma and discrimination, resulting in social exclusion and hindering access to basic social services including health care. The study was conducted by the Fiji Network of People Living with HIV (FJN+) with support from UNDP and covered seven countries: Federated States of Micronesia, Kiribati, Palau, Republic of the Marshall Islands, Samoa, Tonga and Vanuatu. It used a standard questionnaire and methodology developed by a global partnership consisting of the Global Network of People Living

with HIV, the International Community of Women Living with HIV and UNAIDS. The study provides valuable data on the real lived experiences of people living with HIV, and will inform programmes, interventions and policies to ensure more effective HIV responses in the region.

The [Pacific Multi-Country Mapping and Behavioural Study: HIV and STI Risk Vulnerability among Key Populations](#) was released on 14 November 2016. The study examined the behaviour risk factors and social and structural determinants of risk that drive the epidemic among vulnerable groups, such as men who have sex with men, transgender people, sex workers and seafarers, in Cook Islands, Federated States of Micronesia, Kiribati, Palau, Republic of the Marshall Islands, Samoa, Tonga, Tuvalu and Vanuatu. A joint publication by UNDP, UNICEF and the University of New South Wales, the findings indicated an urgent need for reforms in Pacific island countries to adequately address HIV and STIs among vulnerable populations. The research identified key social and legal barriers that are hindering HIV prevention efforts and provided concrete recommendations for policy makers and health programmers. The data produced will be used by countries to support their regional and global reporting obligations and to inform national and regional planning, as well as to empower vulnerable groups to mount strong advocacy cases for change. In addition, the study also conducted population size estimates in each of the nine countries. This population data is a first for many countries in the study, and provides important evidence from which to base HIV prevention programmes for those groups most vulnerable to HIV. Country level reports are [available online](#) with in-depth data and analysis.

In November 2017, the programme supported a public health legal expert to provide technical assistance at the Cook Islands Seminar for Members of Parliament. The seminar was part of an ongoing UNDP-led Pacific Parliamentary Effectiveness Initiative and presented an opportunity to discuss the proposed draft Crimes Bill 2017, including its potential effect on stigma and discrimination, gender-based violence, HIV and STIs, sexual and reproductive health, and inclusion of people of diverse sexual orientation and gender identity. Examples were shared of international good practices and the law's compliance with international human rights and health commitments.

SUMMARY TABLES

Financials

By intervention

Intervention	2015	2016	2017
Diagnosis and treatment of STIs as part of programmes for general population	\$0.00	\$0.00	\$42,371.92
Condoms as part of programmes for MSM and TGs	\$0.00	\$3,335.04	\$17,009.21
HIV testing and counselling as part of programmes for MSM and TGs	\$0.00	\$0.00	\$3,745.44
Diagnosis and treatment of STIs as part of programmes for MSM and TGs	\$0.00	\$0.00	\$0.00
Other interventions for MSM and TGs	\$0.00	\$175,266.44	\$0.00
Behavioral change as part of programmes for MSM and TGs	\$0.00	\$5,475.75	\$98,867.29
Condoms as part of programmes for sex workers and their clients	\$0.00	\$39,191.06	\$80,825.20
HIV testing and counselling as part of programmes for sex workers and their clients	\$0.00	\$0.00	\$5,200.24
Diagnosis and treatment of STIs (sex workers and their clients)	\$0.00	\$8,467.54	\$3,445.33
Other interventions for sex workers and their clients	\$0.00	\$125,190.31	\$0.00
Behavioral change as part of programmes for sex workers and their clients	\$0.00	\$0.00	\$188,273.95
Condoms as part of programmes for other vulnerable populations	\$0.00	\$31,766.95	\$8,606.55
HIV testing and counselling as part of programmes for other vulnerable populations	\$0.00	\$11,975.41	\$17,858.97
Diagnosis and treatment of STIs (other vulnerable populations)	\$0.00	\$25,950.56	\$23,877.05
Other interventions for other vulnerable populations	\$0.00	\$0.00	\$89,249.99
Behavioral change as part of programmes for other vulnerable populations	\$0.00	\$0.00	\$445,567.71
Prong 3: Preventing vertical HIV transmission	\$0.00	\$83,319.64	\$433,340.06
Antiretroviral Therapy (ART)	\$0.00	\$22,433.83	\$27,599.47

Treatment monitoring	\$0.00	\$5,706.50	\$520,444.25
Treatment adherence	\$0.00	\$0.00	\$4,485.45
Prevention, diagnosis and treatment of opportunistic infections	\$0.00	\$27,669.44	\$84,017.85
Counselling and psycho-social support	\$0.00	\$0.00	\$88,944.23
Other interventions for treatment	\$0.00	\$11,634.88	\$752,349.34
Treatment	\$15,678.26	\$997,836.49	\$413,826.35
Key affected populations	\$0.00	\$0.00	\$117,270.33
Case detection and diagnosis	\$37,634.52	\$261,722.56	\$935,524.40
Key affected populations	\$0.00	\$0.00	\$0.00
TB/HIV collaborative interventions	\$0.00	\$8,481.99	\$101,954.00
Treatment: MDR-TB	\$0.00	\$3,412.46	\$77,628.35
Case detection and diagnosis: MDR-TB	\$0.00	\$0.00	\$0.00
Policy advocacy on legal rights	\$0.00	\$4,975.12	\$3,796.05
Social mobilization, building community linkages, collaboration and coordination	\$0.00	\$89,250.90	\$550,885.53
Institutional capacity building, planning and leadership development	\$0.00	\$20,307.73	\$71,014.15
Analysis, review and transparency	\$4,254.55	\$199,752.05	\$242,181.79
Routine reporting	\$0.00	\$65,803.27	-\$273.66
Grant management	\$319,191.97	\$340,785.11	\$658,749.86
Supporting procurement and supply management	\$63,293.62	\$86,920.31	\$8,781.51
Policy, planning, coordination and management	\$294,592.97	\$810,679.09	\$1,114,648.71
Total	\$734,645.89	\$3,467,310.43	\$7,232,066.87

By thematic area

Thematic area	2015	2016	2017
Prevention programmes for general population	\$0.00	\$0.00	\$42,371.92
Prevention programmes for MSM and TGs	\$0.00	\$184,077.23	\$119,621.94
Prevention programmes for sex workers and their clients	\$0.00	\$172,848.91	\$277,744.72
Prevention programmes for other vulnerable populations	\$0.00	\$69,692.92	\$585,160.27
PMTCT	\$0.00	\$83,319.64	\$433,340.06
Treatment, care and support	\$0.00	\$67,444.65	\$1,477,840.59
TB care and prevention	\$53,312.78	\$1,259,559.05	\$1,466,621.08
TB/HIV	\$0.00	\$8,481.99	\$101,954.00
MDR-TB	\$0.00	\$3,412.46	\$77,628.35
Removing legal barriers to access	\$0.00	\$4,975.12	\$3,796.05
Community systems strengthening	\$0.00	\$109,558.63	\$621,899.68
HSS - Health information systems and M&E	\$4,254.55	\$265,555.32	\$241,908.13
Program management	\$677,078.56	\$1,238,384.51	\$1,782,180.08
Total	\$734,645.89	\$3,467,310.43	\$7,232,066.87

By cost input

Cost input	2015	2016	2017
1.0 Human Resources (HR)	\$396,675.89	\$1,550,393.80	\$1,274,848.06
2.0 Travel related costs (TRC)	\$214,463.40	\$1,037,332.45	\$1,745,004.85
3.0 External Professional services (EPS)	\$55,020.00	\$43,867.99	\$894,992.09
4.0 Health Products - Pharmaceutical Products (HPPP)	\$0.00	\$50,303.75	\$128,993.67
5.0 Health Products - Non-Pharmaceuticals (HPNP)	\$0.00	\$227,489.73	\$562,048.73
6.0 Health Products - Equipment (HPE)	\$0.00	\$70,000.00	\$509,050.00
7.0 Procurement and Supply-Chain Management costs (PSM)	\$12,766.84	\$86,558.49	\$149,962.74
8.0 Infrastructure (INF)	\$0.00	\$3,309.58	\$0.00
9.0 Non-health equipment (NHE)	\$2,190.92	\$13,265.04	\$139,711.21
10.0 Communication Material and Publications (CMP)	\$0.00	\$17,590.20	\$246,113.13
11.0 Indirect and Overhead Costs	\$53,528.84	\$349,502.15	\$584,071.68
12. Living support to client/ target population (LSCTP)	\$0.00	\$17,697.25	\$997,270.71
13. Results Based Financing	\$0.00	\$0.00	\$0.00
Total	\$734,645.89	\$3,467,310.43	\$7,232,066.87

Regional performance against key programme indicators 2015-2017

Indicator description	2015	2016	2017
Outcome Indicators			
HIV 0-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy	NA	60%	50%
TB 0-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases	119 *	112	101
TB 0-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse	57 *	44	46
TB 0-2b: Treatment success rate - bacteriologically confirmed TB cases	83%	90%	90%
TB 0-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB)	100%	100%	100%
Coverage Indicators			
GP-4: Percentage of antenatal care attendees tested for syphilis	95%	83%	75%
KP-1a: Percentage of MSM reached with HIV prevention programmes - defined package of services	N/A	0%	4%
KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results	N/A	0%	2%
PMTCT-1: Percentage of pregnant women who know their HIV status	90%	74%	73%
PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission	100%	100%	100%
PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	N/A	100%	100%
TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	53%	51%	75%
DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses	517 *	1019	920
DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses	247*	397	417
DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all new TB cases registered for treatment during a specified period	83%	84%	87%
DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period	83%	90%	90%
TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register	52%	58%	62%
MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)	20%	100%	100%
MDR-TB-other 1: Proportion of detected rifampicin-resistant TB cases (RR-TB) and MDR-TB cases that start treatment within four weeks from diagnosis	100%	100%	33%
DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period	89%	100%	100%
M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines	73%	91%	82%

Notes:

NA: Data not available. Country did not report against this indicator

N/A: Not applicable

*: Data reported is for Jul-Dec 2015 only

Procurement

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
PIMA Bead Standard	2015	HIV/STI/TB Lab Reagents			\$167.00				\$167.00	\$250.50			\$167.00	\$751.50
PIMA CD4 cartridge, 25s	2015	HIV/STI/TB Lab Reagents		\$255.00	\$255.00				\$255.00	\$510.00			\$255.00	\$1,530.00
PIMA Printer Paper	2015	HIV/STI/TB Lab Reagents			\$5.76								\$5.76	\$11.52
PIMA Analyser	2015	Medical Equipments		\$4,575.00										\$4,575.00
TB drug Management Workshop - 18-20 Oct_Nadi	2016	Capacity Development & Building	\$5,513.00	\$6,327.00	\$5,116.00	\$4,249.00	\$5,646.00	\$10,114.00	\$4,840.00	\$3,166.00	\$3,201.00	\$5,345.00	\$3,152.00	\$56,669.00
GeneXpert Training	2016	Capacity Development & Building		\$6,166.67	\$4,138.50			\$6,166.67	\$6,166.67	\$4,138.50	\$4,625.00	\$4,138.50	\$9,138.50	\$44,679.00
CONDOMS 53MM DOTTED MALE CONDOMS, PAC-144	2016	Condoms & Lubricants	\$272.16	\$1,170.29	\$3,755.81		\$19.44	\$85.54	\$944.78	\$1,438.56	\$330.48	\$42.77	\$6,975.07	\$15,034.90
CONDOMS 53MM RIBBED MALE CON-DOMS, PAC-144	2016	Condoms & Lubricants	\$280.54	\$1,199.02	\$3,854.53		\$19.22	\$84.55	\$968.44	\$1,475.71	\$342.03	\$46.12	\$7,151.82	\$15,421.98
CONDOMS 53MM THICK MALE CONDOMS, PAC-144	2016	Condoms & Lubricants	\$56.16	\$250.56	\$803.52		\$4.32	\$17.28	\$198.72	\$306.72	\$69.12	\$12.96	\$1,494.72	\$3,214.08
WATER BASED PERSONAL LUBRICANT, 4MLS, PAC-1000	2016	Condoms & Lubricants	\$450.72	\$112.68	\$1,521.18		\$56.34	\$56.34	\$394.38	\$563.40	\$169.02	\$56.34	\$2,817.00	\$6,197.40
Office Furnitures	2016	Furniture & Fittings								\$5,118.20		\$1,638.78		\$6,756.98
Determine HIV-1/2 Ab Rapid Test Kit + Chase Buffer + Lancets + Capillary Tubes	2016	HIV/STI/TB Lab Reagents	\$950.50	\$3,897.30	\$3,571.50	\$944.80	\$472.40	\$708.60	\$6,967.90	\$9,329.90	\$6,248.30	\$534.30	\$2,682.90	\$36,308.40
Dry Blood Spot Kit, 20s	2016	HIV/STI/TB Lab Reagents	\$80.20	\$85.00	\$165.20		\$80.20	\$165.20	\$245.40	\$165.20	\$165.20	\$165.20	\$165.20	\$1,482.00
INSTI HIV 1+2 antibody rapid test	2016	HIV/STI/TB Lab Reagents	\$72.00	\$720.00	\$72.00	\$144.00	\$72.00	\$72.00	\$72.00	\$216.00	\$72.00	\$72.00	\$216.00	\$1,800.00
Syphilis Rapid Test Kit, 100s	2016	HIV/STI/TB Lab Reagents	\$790.20	\$2,458.40	\$263.40		\$87.80	\$878.00	\$4,829.00	\$8,692.20	\$4,038.80	\$175.60	\$1,229.20	\$23,442.60

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
Tuberculin Injection 1ml vial (Mantoux Test), 20s	2016	HIV/STI/TB Lab Reagents		\$3,150.00	\$7,650.00		\$225.00		\$2,025.00		\$3,825.00	\$337.50	\$9,562.50	\$26,775.00
Unigold HIV 1+2 test, 20s	2016	HIV/STI/TB Lab Reagents	\$30.03	\$40.40	\$40.40	\$40.40	\$40.40	\$40.40	\$80.80	\$70.43	\$40.40	\$40.40	\$40.40	\$504.46
Xpert HIV-1 Cartridges, 10s	2016	HIV/STI/TB Lab Reagents		\$336.00	\$168.00			\$168.00	\$336.00	\$336.00			\$336.00	\$1,680.00
Xpert MTB-RIF Cartridges, 50s	2016	HIV/STI/TB Lab Reagents			\$11,976.00					\$2,994.00	\$1,996.00	\$1,497.00	\$2,495.00	\$20,958.00
TB POSTER - SPUTUM COLLECTION	2016	IEC Materials & Media Campaign	\$75.00	\$150.00	\$150.00	\$75.00	\$75.00	\$1,500.00	\$150.00	\$225.00	\$150.00	\$75.00	\$225.00	\$2,850.00
TB POSTER - TST SCREENING	2016	IEC Materials & Media Campaign	\$75.00	\$150.00	\$150.00	\$75.00	\$75.00	\$1,500.00	\$150.00	\$225.00	\$150.00	\$75.00	\$225.00	\$2,850.00
TB SILICONE WRIST BAND	2016	IEC Materials & Media Campaign								\$25.00				\$25.00
TST BOOKLET	2016	IEC Materials & Media Campaign		\$188.48	\$94.24		\$23.56		\$94.24	\$94.24	\$94.24	\$47.12	\$288.61	\$924.73
TST RULER	2016	IEC Materials & Media Campaign								\$32.30				\$32.30
TV & Radio Spots	2016	IEC Materials & Media Campaign								\$1,047.00				\$1,047.00
UPS 800VA, 230 WATTS	2016	IT Equipments & Printer			\$790.00					\$790.00	\$790.00	\$790.00	\$790.00	\$3,950.00
Computers - Laptops, Desktop & accessories	2016	IT Equipments & Printer					\$1,497.07	\$1,176.00				\$928.23	\$1,929.80	\$5,531.10
Printers	2016	IT Equipments & Printer						\$125.50				\$645.00		\$770.50
CR/DR CASSETTE HOLDER with articulating head	2016	Medical Equipments							\$1,200.00					\$1,200.00
GENEXPERT INSTRUMENT - IV R2.4 MODULE CONFIG - DESKTOP VERSION	2016	Medical Equipments			\$17,500.00					\$17,000.00	\$17,000.00	\$17,500.00	\$17,500.00	\$86,500.00
MinXray Toshiba DR System	2016	Medical Equipments							\$61,000.00					\$61,000.00
Alcohol pre-injection swabs, 100s	2016	Other Consumables, Disposables		\$71.64	\$79.60		\$1.99		\$49.75		\$39.80	\$7.96	\$149.25	\$399.99

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
NEEDLES, 26G, 13MM, 1000s	2016	Other Consumables, Disposables		\$56.92	\$56.92				\$42.69		\$28.46	\$14.23	\$85.38	\$284.60
Syringe, 1ML, INSULIN, 26G, 0.45 X 13MM, 1000s	2016	Other Consumables, Disposables		\$140.08	\$140.08				\$105.06		\$70.04	\$35.02	\$210.12	\$700.40
Xpert Check Kit	2016	Other Consumables, Disposables		\$450.00	\$900.00			\$450.00	\$450.00	\$450.00		\$450.00	\$450.00	\$3,600.00
Apron, Royal Blue, Embroidered w/protective collar	2016	Other Items							\$175.00					\$175.00
COLD BOX, B. KINGS, 90 hours + 24 ice packs	2016	Other Items		\$69.95	\$139.90				\$69.95		\$139.90		\$209.85	\$629.55
Condom Dispenser	2016	Other Items					\$259.40	\$1,037.60	\$778.20	\$1,297.00	\$518.80			\$3,891.00
Data Logger - Multi Use - LIBERO Ti1-L	2016	Other Items		\$214.36	\$428.72		\$428.72		\$214.36		\$428.72	\$214.36	\$643.08	\$2,572.32
SPARE PARTS KIT	2016	Other Items							\$500.00					\$500.00
VACCINE CARRIER. B. KINGS, 43hours + 4 ice packs	2016	Other Items		\$45.45			\$30.30		\$15.15			\$15.15		\$106.05
Azithromycin 500mg Tabs, 3s	2016	Pharmaceuticals								\$1,982.50		\$378.20		\$2,360.70
Azithromycin 500mg tabs, 6s	2016	Pharmaceuticals		\$14.85	\$70.20	\$229.50	\$67.50		\$108.00	\$2,111.40	\$186.30	\$180.90		\$2,968.65
Cefixime 200mg, tabs, 56s	2016	Pharmaceuticals	\$56.30	\$213.94	\$838.87	\$5.63	\$5.63	\$45.04	\$90.08	\$737.53	\$608.04	\$11.26	\$973.99	\$3,586.31
Efavirenz 600mg tabs, 30s	2016	Pharmaceuticals			\$13.20				\$42.90					\$56.10
Emtricitabine 10mg/mL oral solution, 170mLs	2016	Pharmaceuticals								\$918.00				\$918.00
Emtricitabine 200mg+Tenofovir 300mg+Efavirenz 600mg tabs, 30s	2016	Pharmaceuticals		\$78.75					\$67.50					\$146.25
Isoniazid 100mg tabs, 100s	2016	Pharmaceuticals		\$25.50	\$84.15		\$5.10		\$61.20		\$5.10	\$35.70	\$7.65	\$224.40
Isoniazid 300mg tabs, 672s	2016	Pharmaceuticals		\$127.60	\$421.08		\$25.52		\$306.24		\$25.52	\$178.64	\$38.28	\$1,122.88

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
Lamivudine 150mg+Zidovudine 300mg tabs, 60s	2016	Pharmaceuticals		\$13.50	\$27.00					\$121.50				\$162.00
Lamivudine 150mg+Zidovudine 300mg+Nevirapine 200mg tabs, 60s	2016	Pharmaceuticals			\$61.25				\$105.00	\$61.25				\$227.50
Lamivudine 300mg+Tenofovir 300mg tabs, 30s	2016	Pharmaceuticals	\$5.25	\$26.15	\$5.20	\$5.25	\$5.25	\$67.65	\$5.25	\$9.95	\$5.25		\$15.65	\$150.85
Lamivudine 300mg+Tenofovir 300mg+Efavirenz 600mg tabs, 30s	2016	Pharmaceuticals		\$410.60	\$10.30			\$10.30	\$57.60	\$39.10	\$100.90		\$506.60	\$1,135.40
Lamivudine 30mg+Zidovudine 60mg+Nevirapine 50mg dispersible tabs, 60s	2016	Pharmaceuticals			\$29.20									\$29.20
Lopinavir 200mg+Ritonavir 50mg tabs, 120s	2016	Pharmaceuticals						\$379.40		\$630.00			\$126.00	\$1,135.40
Lopinavir 80mg+Ritonavir 20mg Oral Solution, 60mLs	2016	Pharmaceuticals								\$120.00				\$120.00
Nevirapine 10mg/mL oral solution, 100mLs	2016	Pharmaceuticals		\$7.20	\$1.80			\$3.60	\$1.80	\$7.20			\$10.95	\$32.55
Nevirapine 200mg tabs, 60s	2016	Pharmaceuticals								\$9.60				\$9.60
Procaine benzyl penicillin powder for injection 1g (1 million IU), Vial	2016	Pharmaceuticals	\$1.40	\$11.13	\$3.36	\$1.47	\$0.42		\$20.79	\$12.81	\$6.93	\$0.84	\$38.85	\$98.00
Sulf. 100mg + Trimet. 20mg, dispersible tabs; 100s	2016	Pharmaceuticals			\$23.76					\$8.64	\$5.40			\$37.80
Sulf. 400mg + Trimet. 80mg Tabs, 100s	2016	Pharmaceuticals		\$75.52	\$75.52				\$84.48	\$84.48	\$44.80		\$47.36	\$412.16
Tenofovir 40mg/g Oral Powder, 60g	2016	Pharmaceuticals								\$925.00				\$925.00

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
IATA Certification & Regional TB Lab Technicians Training_7-11 Aug-Nadi	2017	Capacity Development & Building	\$5,331.31	\$8,987.88	\$11,578.79			\$7,175.25		\$3,909.09	\$3,162.63	\$3,671.72	\$7,163.13	\$50,979.80
mSupply Training	2017	Capacity Development & Building							\$10,500.00			\$5,650.00		\$16,150.00
GeneXpert Training	2017	Capacity Development & Building	\$4,250.00		\$4,250.00									\$8,500.00
Bio Safety cabinet Fumigation	2017	Capacity Development & Building	\$4,670.00		\$4,080.00	\$4,980.00				\$5,690.00	\$5,600.00	\$3,850.00	\$6,100.00	\$34,970.00
SD Duo Pilot Training - 27-28 June - Nadi	2017	Capacity Development & Building			\$4,422.00			\$9,820.00		\$4,501.00	\$3,479.00		\$3,580.00	\$25,802.00
CONDOMS 53MM DOT-TED MALE CONDOMS, PAC-144	2017	Condoms & Lubricants				\$31.10		\$97.20		\$155.52				\$283.82
CONDOMS 53MM RIBBED MALE CON-DOMS, PAC-144	2017	Condoms & Lubricants				\$30.74		\$76.86		\$107.60				\$215.20
CONDOMS 53MM THICK MALE CONDOMS, PAC-144	2017	Condoms & Lubricants				\$8.64		\$51.84		\$30.24				\$90.72
WATER BASED PERSONAL LUBRICANT, 4MLS, PAC-1000	2017	Condoms & Lubricants	\$868.20	\$5,498.60		\$231.52	\$57.88	\$403.62	\$4,109.48	\$7,350.76	\$1,447.00	\$173.64	\$30,502.76	\$50,643.46
Office Furnitures	2017	Furniture & Fittings			\$2,026.26									\$2,026.26
Determine HIV-1/2 Ab Rapid Test Kit + Chase Buffer + Lancets + Capillary Tubes	2017	HIV/STI/TB Lab Reagents	\$1,260.00	\$9,270.00	\$1,620.00	\$1,620.00	\$630.00	\$1,710.00	\$6,930.00	\$13,680.00	\$8,950.00	\$940.00	\$2,570.00	\$49,180.00
HIV/Syphilis Duo RDTs, PAC-25 Test	2017	HIV/STI/TB Lab Reagents	\$212.50		\$1,096.50			\$453.00		\$3,169.50	\$1,952.50		\$1,712.00	\$8,596.00
INSTI HIV 1/2 Confirmatory, One test Kit	2017	HIV/STI/TB Lab Reagents	\$55.45	\$245.35	\$79.00	\$49.50	\$43.55	\$87.10	\$178.25	\$98.75	\$126.60	\$99.00	\$259.40	\$1,321.95
INSTI HIV 1+2 antibody rapid test	2017	HIV/STI/TB Lab Reagents			\$144.00									\$144.00

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
PIMA Bead Standard	2017	HIV/STI/TB Lab Reagents		\$83.50	\$250.50					\$167.00			\$167.00	\$668.00
PIMA CD4 cartridge, 25s	2017	HIV/STI/TB Lab Reagents		\$255.00	\$255.00				\$255.00	\$255.00			\$255.00	\$1,275.00
PIMA CD4 cartridge, EA	2017	HIV/STI/TB Lab Reagents			\$71.40				\$81.60					\$153.00
Syphilis Rapid Test Kit, 100s	2017	HIV/STI/TB Lab Reagents	\$450.00	\$2,160.00		\$900.00	\$180.00	\$450.00	\$2,790.00	\$3,735.00	\$2,250.00	\$450.00	\$3,600.00	\$16,965.00
Unigold HIV 1+2 test, 20s	2017	HIV/STI/TB Lab Reagents	\$27.72	\$254.10	\$85.47	\$27.72	\$27.72	\$27.72	\$55.44	\$110.88	\$55.44	\$27.72	\$113.19	\$813.12
Xpert CT/NG Cartridges, 10s	2017	HIV/STI/TB Lab Reagents	\$1,944.00	\$31,104.00	\$34,992.00			\$7,776.00	\$17,496.00	\$58,320.00	\$19,440.00	\$5,832.00	\$25,272.00	\$202,176.00
Xpert HIV-1 Cartridges, 10s	2017	HIV/STI/TB Lab Reagents		\$168.00	\$168.00			\$336.00	\$168.00	\$168.00	\$168.00		\$168.00	\$1,344.00
Xpert MTB-RIF Cartridges, 50s	2017	HIV/STI/TB Lab Reagents	\$499.00		\$16,966.00					\$6,986.00	\$2,994.00	\$1,497.00	\$4,990.00	\$33,932.00
XPRT URINE COLLECTION KIT, 10s	2017	HIV/STI/TB Lab Reagents	\$182.40	\$2,918.40	\$3,283.20			\$729.60	\$1,641.60	\$5,472.00	\$1,824.00	\$547.20	\$2,371.20	\$18,969.60
STI/HIV Awareness Brouchures	2017	IEC Materials & Media Campaign		\$350.00	\$950.00			\$3,560.00		\$7,055.00		\$1,850.00		\$13,765.00
Media Awareness Campaigns - Digicel	2017	IEC Materials & Media Campaign				\$1,734.09				\$13,555.64	\$1,954.29		\$40,859.37	\$58,103.39
TV & Radio Spots	2017	IEC Materials & Media Campaign								\$5,235.00				\$5,235.00
TB POSTER - SPUTUM COLLECTION - KIRIBATI VENECLAR	2017	IEC Materials & Media Campaign			\$750.00									\$750.00
KANIKINAENEI POSTER-KIRIBATI VENECLAR	2017	IEC Materials & Media Campaign			\$750.00									\$750.00
ZN STAIN POSTER	2017	IEC Materials & Media Campaign	\$20.00	\$80.00	\$30.00	\$15.00	\$15.00	\$30.00	\$40.00	\$40.00	\$30.00	\$15.00	\$80.00	\$395.00
OTHER AWARENESS MATERIALS	2017	IEC Materials & Media Campaign									\$2,612.25			\$2,612.25
PIMA PRINTER	2017	IT Equipments & Printer			\$350.00								\$350.00	\$700.00
UPS 1500VA, 895 WATTS	2017	IT Equipments & Printer	\$790.00	\$790.00	\$790.00					\$790.00	\$790.00		\$790.00	\$4,740.00
Laptops	2017	IT Equipments & Printer			\$5,689.29		\$1,497.07							\$7,186.36

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
Projector	2017	IT Equipments & Printer			\$1,778.28									\$1,778.28
Printers & toners	2017	IT Equipments & Printer			\$1,682.83									\$1,682.83
ALERE PIMA ANALYSER	2017	Medical Equipments			\$5,500.00								\$5,500.00	\$11,000.00
CR/DR CASSETTE HOLDER with articulating head	2017	Medical Equipments		\$1,440.00	\$1,440.00							\$1,440.00	\$1,440.00	\$5,760.00
GENEXPERT INSTRUMENT - IV R2 4 MODULE CONFIG - DESK-TOP/ LAPTOP VERSION	2017	Medical Equipments	\$17,500.00	\$17,500.00	\$35,000.00				\$35,000.00	\$35,000.00	\$17,500.00		\$35,000.00	\$192,500.00
MinXray Toshiba DR System	2017	Medical Equipments		\$62,536.50	\$62,536.50							\$62,536.50	\$62,536.50	\$250,146.00
Bio Safety cabinet - Class II	2017	Medical Equipments			\$45,931.29		\$11,482.82							\$57,414.11
Ambulance	2017	Motor Vehicles, Boats & Engines			\$72,852.76			\$72,852.76						\$145,705.52
N95 Respirator Mask, PAC-20	2017	Other Consumables, Disposables			\$6,281.00								\$242.04	\$6,523.04
Apron, Royal Blue, Embroidered w/protective collar	2017	Other Items		\$210.00	\$210.00							\$210.00	\$210.00	\$840.00
CareSens N B/Glucose Monitoring System	2017	Other Items			\$580.00									\$580.00
CareSens N Strips, 50s	2017	Other Items			\$900.00									\$900.00
Condom Dispenser	2017	Other Items				\$648.50	\$259.40			\$2,464.30	\$4,798.90			\$8,171.10
PIMA ANALYSER BAG	2017	Other Items			\$180.00								\$180.00	\$360.00
PIMA Printer Paper	2017	Other Items			\$5.76					\$5.76				\$11.52
SPARE PARTS KIT	2017	Other Items		\$600.00	\$600.00							\$600.00	\$600.00	\$2,400.00
System Transport case, hardigg case AL5824-1119AC (FOC)	2017	Other Items		\$500.00	\$500.00							\$500.00	\$500.00	\$2,000.00
Thermoelectric cooler, 7L, 12V - TropiCool	2017	Other Items					\$173.70	\$1,389.60	\$694.80		\$347.40	\$694.80		\$3,300.30
VACCINE CARRIER. B. KINGS, 43hours + 4 ice packs	2017	Other Items	\$370.80	\$72.10	\$463.50	\$20.60	\$10.30			\$123.60	\$123.60		\$525.30	\$1,709.80

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
TB Register	2017	Other Items	\$82.60	\$330.40	\$165.20	\$82.60	\$82.60	\$82.60	\$165.20	\$165.20	\$82.60	\$82.60	\$330.40	\$1,652.00
TB Treatment Card	2017	Other Items	\$7.80	\$58.30	\$155.60	\$7.80	\$7.80	\$11.70	\$97.20	\$19.40	\$11.70	\$19.40	\$46.70	\$443.40
TB Lab Register	2017	Other Items	\$114.20	\$456.70	\$228.40	\$114.20	\$114.20	\$114.20	\$228.40	\$228.40	\$114.20	\$114.20	\$456.70	\$2,283.80
TB Lab Request Form	2017	Other Items	\$19.30	\$77.20	\$38.60	\$19.30	\$19.30	\$19.30	\$38.60	\$38.60	\$19.30	\$19.30	\$77.20	\$386.00
Azithromycin 500mg Tabs, 3s	2017	Pharmaceuticals	\$103.70	\$1,844.00	\$997.18		\$12.20	\$92.24	\$383.00	\$8,585.84	\$316.92		\$610.00	\$12,945.08
Efavirenz 600mg tabs, 30s	2017	Pharmaceuticals			\$147.44				\$100.12					\$247.56
Emtricitabine 10mg/mL oral solution, 170mLs	2017	Pharmaceuticals								\$1,026.00				\$1,026.00
Emtricitabine 200mg+Tenofovir 300mg+Efavirenz 600mg tabs, 30s	2017	Pharmaceuticals		\$76.00					\$522.75					\$598.75
Lamivudine 150mg+Zidovudine 300mg tabs, 60s	2017	Pharmaceuticals			\$308.20				\$127.80	\$464.40				\$900.40
Lamivudine 150mg+Zidovudine 300mg+Nevirapine 200mg tabs, 60s	2017	Pharmaceuticals			\$127.40				\$251.00	\$226.35			\$73.80	\$678.55
Lamivudine 300mg+Tenofovir 300mg tabs, 30s	2017	Pharmaceuticals	\$5.20	\$15.15	\$9.95	\$5.20	\$5.20	\$166.90	\$10.40	\$99.50	\$5.20	\$5.20	\$66.50	\$394.40
Lamivudine 300mg+Tenofovir 300mg+Efavirenz 600mg tabs, 30s	2017	Pharmaceuticals	\$10.50	\$720.20	\$39.00	\$10.50	\$10.50	\$18.00	\$105.00	\$39.00	\$177.00	\$10.50	\$346.50	\$1,486.70
Lamivudine 30mg+Zidovudine 60mg+Nevirapine 50mg dispersible tabs, 60s	2017	Pharmaceuticals			\$80.00									\$80.00
Lopinavir 200mg+Ritonavir 50mg tabs, 120s	2017	Pharmaceuticals						\$612.00		\$1,527.00			\$260.00	\$2,399.00
Nevirapine 10mg/mL oral solution, 100mLs	2017	Pharmaceuticals	\$1.80	\$3.60	\$5.40	\$3.60	\$1.80		\$3.60		\$3.60	\$3.60		\$27.00
Nevirapine 200mg tabs, 60s	2017	Pharmaceuticals								\$36.00				\$36.00

Items	Year	Classification	Cook Islands	Federated States of Micronesia	Kiribati	Nauru	Niue	Palau	Republic of the Marshall Islands	Samoa	Tonga	Tuvalu	Vanuatu	Total
Procaine benzyl penicillin powder for injection 1g (1 million IU), Vial	2017	Pharmaceuticals								\$14.00		\$3.50		\$17.50
Sulf. 400mg + Trimet. 80mg Tabs, 100s	2017	Pharmaceuticals				\$12.80								\$12.80
Tenofovir 40mg/g Oral Powder, 60g	2017	Pharmaceuticals								\$3,330.00				\$3,330.00
MDR TB Drugs	2017	Pharmaceuticals			\$11,436.00								\$7,624.00	\$19,060.00
Total			\$47,484.94	\$181,889.92	\$410,475.85	\$16,323.46	\$23,854.62	\$132,995.16	\$176,409.57	\$261,711.15	\$125,856.68	\$126,527.96	\$319,884.18	\$1,823,413.48

UNDP would like to express our sincere appreciation to all of the partners named in this report. Without your dedicated efforts, the achievements would not have been possible.

CONTACT US

UNDP Pacific Office
Level 2, Kadavu House 414 Victoria Parade
Suva, Fiji
Phone: +679 331 2018
Email: globalfund.pacific@undp.org

FOLLOW US ON:

 [@GlobalFundPacific](https://twitter.com/GlobalFundPacific)

SUBSCRIBE TO OUR MAILING LIST:

 <http://eepurl.com/cARtel>